Newleos
MA - BostonBiotechnology
Focus: Newleos is a Boston-based biotech focused on psychiatry treatments, specifically targeting anxiety and substance abuse disorders. The company operates as a pre-revenue biotech with early-stage pipeline assets.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Open Jobs
1
Should You Work at Newleos?
AI assessmentNewleos is a high-risk, high-upside early-stage bet suited for mission-driven professionals comfortable with uncertainty and eager to build from the ground up.
Why Work Here
- Ground-floor opportunity at an early-stage biotech with focused pipeline in high-need CNS indications (social anxiety, alcohol use disorder)
- Access to regulatory affairs leadership roles as company scales clinical programs from Phase 1–2
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
NTX-1472
Social Anxiety Disorder (SAD)Clinical Trials (1)
NCT07323784A Study of NTX-1472 in Social Anxiety Disorder
Phase 2Help build intelligence for Newleos
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.